Vol.27/No.2

Experts across tumor types share their insights on the notable FDA regulatory decisions of 2025.

Phase 1 data demonstrate early safety and efficacy signals with targeting CBP/p300 in patients with solid tumors.

Lung cancer experts stress the importance of lung cancer screening and discuss ways that technological advances are transforming screening processes and outcomes.

Maurie Markman, MD, discusses the essential yet often complex role associated with interpreting numbers and measurements in oncology.

Experts convene during an OncLive Peer Exchange to discuss the evolving treatment paradigm in HR-positive, HER2-negative breast cancer.

In the BARCODE1 screening study, prostate cancer testing by polygenic risk score identified a higher percentage than PSA testing or MRI.

Pancreatic ductal adenocarcinoma remains highly lethal due to late presentation, treatment resistance, and limited drug delivery with standard systemic therapies.

Adjuvant cemiplimab significantly cut recurrence risk and improved disease-free survival in high-risk CSCC, establishing a new standard of care.